Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 27, 2014-- Covidien plc (NYSE: COV) today announced that its Japanese subsidiary, Covidien Japan Inc., has received Shonin approval from the Japanese...
DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 24, 2014-- Covidien plc (NYSE: COV) today announced financial results for the first quarter of fiscal 2014 (October - December 2013). First-quarter net sales of
MUMBAI, India--(BUSINESS WIRE)--Jan. 23, 2014-- Further developing its capabilities in a key emerging market, Covidien (NYSE:COV) has officially opened its first training and education center in...
DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 23, 2014-- Covidien plc. (NYSE: COV) does not infringe certain patents held by Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, according to a...
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 22, 2014-- Expanding its industry-leading vessel and tissue sealing portfolio, Covidien (NYSE:COV) received U.S. Food and Drug Administration (FDA) 510(k)...
MINNEAPOLIS - January 22, 2014 - Medtronic, Inc. (NYSE: MDT), today announced that the Medtronic SureScan® pacing systems - the first and only pacing systems in the United States that have been...
MINNEAPOLIS - Jan. 22, 2014 - Medtronic, Inc. (NYSE: MDT) announced that the U.S. Supreme Court ruled 9-0 in favor of Medtronic that the burden of proving infringement rests with the party...
DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 21, 2014-- Covidien plc (NYSE: COV) today announced it will exit its OneShot™ Renal Denervation program. This voluntary action is primarily in response to...
MINNEAPOLIS - Jan. 17, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval of the self-expanding transcatheter CoreValve® System for severe...
DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 16, 2014-- Covidien plc (NYSE: COV) today announced that its Board of Directors has declared a quarterly cash dividend of $0.32 per ordinary share. The...